ClinicalTrials.gg
RecruitingNCT07577414Updated Jun 29, 2026

Safety and Efficacy of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Congenital Diaphragmatic Hernia (CDH)

An interventional study of FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) in Congenital Diaphragmatic Hernia, sponsored by Dr Erin Perrone. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Dr Erin Perrone · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Planned enrollment
13th of 36
40 · median 21
Started
2026
with 4 others
No phase
28 of 45
18 open now
Primary completion
2036-04
later than 25 of 27 live
Registered
44th of 45
by date
Lead sponsor
2 of 45
Dr Erin Perrone

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2026, is one of 28 with no phase, reaches primary completion later than 25 of the 27 other live ones, and was the 44th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine if babies with left or right-sided CDH that undergo the FETO procedure survive more often and have fewer long-term complications than babies that have similar left or right-sided CDH that elect not to have the FETO procedure performed during pregnancy.

03

Conditions studied

  • Congenital Diaphragmatic Hernia

Keywords

  • Pregnant
  • Fetal Endoscopic tracheal occlusion
  • Standard of Care arm
  • Goldballoon Detachable Balloon (GOLDBAL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

FETO Intervention Arm: Inclusion Criteria:

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability (meets psychosocial criteria below) for the duration of the study
  • Pregnant women, age 18 years and older
  • Singleton pregnancy
  • Normal fetal karyotype, Chromosomal Microarray (CMA) with non-pathologic variants, Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS). Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is >26 weeks.
  • Gestational age at enrollment prior to 29w6d
  • Fetal CDH with intrathoracic liver herniation with either:

    • Isolated left CDH with Observed/Expected (o/e) Lung to Head Ratio (LHR) \<30% at enrollment (18w0d-29w5d)
    • Isolated right CDH with o/e LHR \<45% at enrollment (18w0d-29w5d)
  • Cervical length by transvaginal ultrasound >20 mm within 24hours of FETO procedure
  • Meets psychosocial criteria

    • Willing to reside within 30 minutes of Von Voigtlander Women's Hospital and ability to maintain follow up appointments
    • Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with participant for the duration of the pregnancy near Von Voigtlander Women's Hospital
    • Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work (work from home approved by Principal Investigator is okay)

Expectant Management Arm: Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability (meets psychosocial criteria below) for the duration of the study
  • Pregnant women, age 18 years and older
  • Singleton pregnancy
  • Normal fetal karyotype, CMA with non-pathologic variants, WES or WGS. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is >26 weeks. (non-intervention arm can have karyotype or microarray prenatally or postnatally)
  • Gestational age at enrollment prior to 29w6d
  • Fetal CDH with intrathoracic liver herniation with either:
  • Isolated left CDH with o/e LHR \<30% at enrollment (18w0d-29w5d)
  • Isolated right CDH with o/e LHR \<45% at enrollment (18w0d-29w5d)
  • Meets psychosocial criteria

    • Ability to maintain follow up appointments

FETO Intervention Arm: Exclusion Criteria:

  • Patient \<18 years of age
  • Multi-fetal pregnancy
  • History of natural rubber latex allergy
  • Preterm labor, short cervix (\<20mm within 24 hours of FETO balloon insertion procedure), or uterine anomaly strongly predisposing to preterm labor, placenta previa
  • History of incompetent cervix with or without cerclage
  • Psychosocial ineligibility

    • Inability to reside within 30 minutes of Von Voigtlander Women's Hospital or inability to maintain follow up appointments
    • Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude participant as a potential candidate (per protocol).
  • Bilateral CDH, isolated Left Congenital Diaphragmatic Hernia (LCDH) with o/e LHR > 30% (measured at 180 to 295 weeks), isolated Right Congenital Diaphragmatic Hernia (RCDH) with o/e LHR >45% (measured at 180 to 295 weeks) as determined by ultrasound
  • No liver herniation into the thoracic cavity.
  • Additional fetal anomaly or genetic/chromosomal abnormalities recognized to alter survival prognosis (i.e., congenital heart disease) or presence of an underlying genetic syndrome (i.e. Fryns) by ultrasound, MRI or echocardiogram at the fetal treatment center.
  • Maternal to elective fetoscopic surgery or severe maternal medical condition in pregnancy
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment and/or surgery
  • Maternal-fetal Rh isoimmunization, Kell sensitization, or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  • Maternal (HIV), with positive surface antigen, with presence of virus in maternal blood due to risk of fetal transmission during the procedure. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment
  • No safe or technically feasible fetoscopic approach to balloon placement
  • Uterine anomalies such as large fibroids or Mullerian duct abnormality
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy

Expectant Management Arm: Exclusion Criteria:

  • Patient \<18 years of age
  • Multi-fetal pregnancy
  • Preterm labor, short cervix (\<20mm), or uterine anomaly strongly predisposing to preterm labor, placenta previa
  • History of incompetent cervix with or without cerclage
  • Psychosocial ineligibility

    • Inability to maintain follow up appointments
    • Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude participant as a potential candidate.
  • Bilateral CDH, isolated LCDH with o/e LHR > 30% (measured at 180 to 295 weeks), isolated RCDH with o/e LHR >45% (measured at 180 to 295 weeks), or any isolated CDH without intrathoracic liver herniation as determined by ultrasound
  • Additional fetal anomaly or genetic/chromosomal abnormalities recognized to alter survival prognosis (i.e. congenital heart disease) or presence of an underlying genetic syndrome (i.e. Fryns) by ultrasound, Magnetic Resonance Imaging (MRI) or echocardiogram at the fetal treatment center Placental abnormalities (per protocol)
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    FETO surgery Intervention Arm

    Eligible participants that choose the FETO Intervention Arm, will undergo two surgeries, one to place the balloon and a second to remove the balloon before delivery.

    Device: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)

  • No intervention
    Expectant Management Arm

    Participants choose to undergo the expectant management, or routine care, of carrying a baby with Congenital Diaphragmatic Hernia (CDH). Participants will undergo a comprehensive fetal evaluation at Michigan Medicine's Fetal Diagnosis and Treatment Center (FDTC) to confirm the diagnosis and severity of the CDH. Eligibility will be based on the results of the clinical assessment.

Interventions

  • DeviceFETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)

    This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.

06

What researchers measure

Primary outcomes

  1. Compare neonatal survival to discharge in LCDH

    Time frame: 6-12 months (birth to discharge)

  2. Compare neonatal survival to discharge in RCDH

    Time frame: 6-12 months (birth to discharge)

  3. Number of successful placements the of FETO balloon Gestational age of 27 weeks 0 days gestation to 29 weeks 6 days gestation

    Time frame: 27weeks 0 days gestation to 29 weeks 6 days gestation

  4. Number of successful retrievals/puncture of the FETO balloon Gestational age of 33 weeks 0 days to 35 weeks 0 days

    Time frame: Removal prior to delivery at approximately 34 weeks of gestation

  5. Number of FETO procedure complications

    FETO procedure complications include: Failure of the FETO insertion procedure; FETO device dislodgement potentially requiring a second FETO insertion; Fetal intraoperative injury; Procedural hemorrhage: Bleeding from insertion site or Abruptions; Post-procedural hemorrhage; Preterm premature rupture of membranes; Preterm delivery; Chorioamnion separation; Chorioamnionitis; Polyhydramnios; Oligohydramnios; Emergent removal due to obstetrical complication; Failed percutaneous or fetoscopic removal requiring cesarean section or Ex-Utero Intrapartum Therapy(EXIT) procedure for removal; Neonatal death due to asphyxia if delivery before FETO removal; Non-reassuring fetal heart rate monitoring.

    Time frame: Balloon placement to delivery (27 weeks up to delivery approximately 40 weeks)

Secondary outcomes

  1. Fetal lung growth difference on MRI via o/e Total Fetal Lung Volume (TFLV) (FETO Intervention Arm)

    Fetal MRI done prior to balloon placement and again done at approximately 2 weeks of balloon retrieval. Fetal lung growth (difference between 1st and 2nd MRIs will be calculated for FETO intervention arm only).

    Time frame: Baseline (prior to balloon placement) and approximately 2 weeks after balloon retrieval

  2. Fetal lung growth difference based on prenatal ultrasound via o/e LHR (Both Arms)

    Prenatal ultrasound (US) will measure the o/e LHR at weekly visits while the balloon is in place (FETO intervention arm) or at routine visits per standard of care (SOC) (expectant arm). Fetal lung growth will be calculated as the difference between the o/e LHR pre- balloon placement (or 29 + 1 week in control) and the o/e LHR immediately prior to balloon removal/puncture (or 34 + 1 week in control).

    Time frame: Baseline (prior to balloon placement) and immediately prior to balloon removal and SOC arm 29 + 1 week and 34 +1 week

  3. Long-term outcome measure infant survival rate

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  4. Presence of pulmonary hypertension

    Determination of the ratio of the tricuspid regurgitation jet (estimation of the right ventricular systolic pressure) to systemic blood pressure where the is an objective measurement used to estimate the pulmonary artery pressure. Will be recorded as absent/none, systemic or suprasystemic.

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  5. Presence of need for supplemental oxygen

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  6. Periventricular leukomalacia at <2 months postnatally

    Time frame: After birth at 2 months

  7. Infant sepsis

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  8. Intraventricular hemorrhage (grade 0-III)

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  9. Retinopathy of prematurity (grade 3 or higher)

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  10. Gastroesophageal reflux

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  11. Number and cause of infant hospital readmissions

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  12. Long-term outcome measure childhood growth failure

    Childhood growth failure: weight gain velocity or decline \>2 in weight, for length Z score.

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  13. Recurrence of CDH repair

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

  14. Bowel obstruction

    Time frame: After birth at 6, 12, 18, and 24 months (+ 2 months) of corrected age

  15. Neurodevelopmental delay

    Bayley Scales of Infant and Toddler Development- III(BSID)\>2 Standard deviation (SD) below mean, or other categorization at 24 months

    Time frame: 24 months (+ 2 months) of corrected age

  16. Bronchopulmonary dysplasia

    Time frame: After birth at 6,12, 18, and 24 months (+ 2 months) of corrected age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2036, 118 months after the start.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 118 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2026
First posted
May 11, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Apr 2036
CompletionEst.
Apr 2038
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07577414
Lead sponsor
Dr Erin Perrone
Responsible party
Dr Erin Perrone (Associate Professor of Surgery, University of Michigan) — Sponsor-investigator
First posted
May 11, 2026
Start date
Jun 17, 2026
Primary completion
Apr 2036 (estimated)
Completion
Apr 2038 (estimated)
Last update
Jun 29, 2026

Study contacts

Irene Carter
Contact
irenestc@med.umich.edu
734-615-3883
Erin Perrone, MD
Contact
eperrone@med.umich.edu
734-936-8464
Erin Perrone, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion